ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,584.54
      -0.88%
      US Tech 100
      19,681.20
      -2.17%
      Dow Jones
      39,753.75
      0.08%
      Brent Oil
      85.275
      0.19%
      Bitcoin
      57,259.13
      -0.16%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Innate Pharma SA (IPHA)

      7. Innate Pharma SA (IPHA) News

      IPHA

      Innate Pharma (IPHA)

      Innate Pharma SA
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:IPHA
      DateTimeSourceHeadlineSymbolCompany
      12:21PMiHub NewswireFeaturedCannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing
      10/19/20231:00AMBusiness WireInnate Pharma publie son calendrier financier pour 2024NASDAQ:IPHAInnate Pharma SA
      10/19/20231:00AMBusiness WireInnate Pharma 2024 Financial CalendarNASDAQ:IPHAInnate Pharma SA
      10/19/20231:00AMBusiness WireInnate Pharma 2024 Financial CalendarNASDAQ:IPHAInnate Pharma SA
      10/16/20231:00AMBusiness WireInnate Pharma Announces Abstracts Selected for ESMO Congress 2023NASDAQ:IPHAInnate Pharma SA
      10/16/20231:00AMBusiness WireInnate Pharma Announces Abstracts Selected for ESMO Congress 2023NASDAQ:IPHAInnate Pharma SA
      10/16/20231:00AMBusiness WireInnate Pharma annonce les abstracts sélectionnés au congrès de l’ESMO 2023NASDAQ:IPHAInnate Pharma SA
      10/09/20231:00AMBusiness WireNumber of Shares and Voting Rights of Innate Pharma as of October 3, 2023NASDAQ:IPHAInnate Pharma SA
      10/09/20231:00AMBusiness WireNouveau nombre d’actions et de droits de vote d’Innate Pharma au 3 octobre 2023NASDAQ:IPHAInnate Pharma SA
      10/09/20231:00AMBusiness WireNumber of Shares and Voting Rights of Innate Pharma as of October 3, 2023NASDAQ:IPHAInnate Pharma SA
      10/05/20238:14AMDow Jones NewsInnate Pharma Shares Fall Premarket on FDA Partial Study HoldNASDAQ:IPHAInnate Pharma SA
      10/05/20231:00AMBusiness WireInnate Pharma Provides Update on Lacutamab Clinical ProgramNASDAQ:IPHAInnate Pharma SA
      10/05/20231:00AMBusiness WireInnate Pharma annonce une mise à jour sur le programme clinique de lacutamabNASDAQ:IPHAInnate Pharma SA
      10/05/20231:00AMBusiness WireInnate Pharma Provides Update on Lacutamab Clinical ProgramNASDAQ:IPHAInnate Pharma SA
      09/22/20231:00AMBusiness WireInnate Pharma présente les données d’efficacité intermédiaires de l’essai de Phase 2 TELLOMAK actualisées selon les critères Olsen 2022 au congrès annuel de l'EORTC CLTG 2023NASDAQ:IPHAInnate Pharma SA
      09/22/20231:00AMBusiness WireInnate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023NASDAQ:IPHAInnate Pharma SA
      09/22/20231:00AMBusiness WireInnate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023NASDAQ:IPHAInnate Pharma SA
      09/14/20236:27AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
      09/14/20236:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
      09/14/20231:00AMBusiness WireInnate Pharma présente ses résultats financiers et l’avancée de son portefeuille au premier semestre 2023NASDAQ:IPHAInnate Pharma SA
      09/14/20231:00AMBusiness WireInnate Pharma Reports First Half 2023 Financial Results and Business UpdateNASDAQ:IPHAInnate Pharma SA
      09/14/20231:00AMBusiness WireInnate Pharma Reports First Half 2023 Financial Results and Business UpdateNASDAQ:IPHAInnate Pharma SA
      08/29/20236:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
      08/29/20231:00AMBusiness WireInnate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business UpdateNASDAQ:IPHAInnate Pharma SA
      08/29/20231:00AMBusiness WireInnate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business UpdateNASDAQ:IPHAInnate Pharma SA
      08/29/20231:00AMBusiness WireInnate Pharma annonce sa participation à de prochaines conférences investisseurs et organise une conférence téléphonique pour ses résultats financiers au premier semestre 2023NASDAQ:IPHAInnate Pharma SA
      08/10/20231:00AMBusiness WireInnate Pharma to Participate in Upcoming Investor ConferenceNASDAQ:IPHAInnate Pharma SA
      08/10/20231:00AMBusiness WireProchain rendez-vous investisseurs d'Innate PharmaNASDAQ:IPHAInnate Pharma SA
      07/11/20236:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
      07/11/20231:00AMBusiness WireFirst Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple MyelomaNASDAQ:IPHAInnate Pharma SA
       Showing the most relevant articles for your search:NASDAQ:IPHA